"The Iliac Stent Market was valued at $ 1263 million in 2025 and is projected to reach $ 2412 million by 2034, growing at a CAGR of 7.45%."
The iliac stent market forms an important segment of the broader peripheral vascular intervention industry and focuses on endovascular devices used to restore and maintain blood flow in the common and external iliac arteries, as well as in selected aneurysmal anatomies involving the iliac bifurcation. These stents are widely used in the treatment of atherosclerotic stenosis, occlusive disease, restenotic lesions, bifurcation involvement, and complex aortoiliac conditions, while iliac branch systems are increasingly relevant where preservation of internal iliac artery flow is clinically important. The market’s main end-use settings include hospitals, vascular surgery units, catheterization laboratories, hybrid operating rooms, and specialized endovascular centers, where minimally invasive approaches are preferred for their ability to reduce recovery time and improve procedural efficiency. Demand is influenced by the need for durable luminal support, high radial strength, placement accuracy, flexibility in tortuous anatomy, and reliable outcomes in calcified lesions. The market is also differentiated by product type, with self-expanding stents commonly preferred for flexibility and vessel conformity, balloon-expandable stents used where deployment precision is critical, and covered stents chosen for complex lesions, bifurcation disease, and situations where lesion exclusion or enhanced sealing is required.
From a market development perspective, the iliac stent segment is benefiting from the growing preference for endovascular-first treatment strategies, increasing physician confidence in managing complex iliac lesions, and continuous advances in covered, branch-preserving, and precision-deployment platforms. Demand is being reinforced by the sustained burden of peripheral artery disease and aortoiliac occlusive disease, especially among aging populations and patients with diabetes, smoking history, hypertension, dyslipidemia, and related cardiovascular risk factors. Current momentum is strongest around procedural refinement, including improved radiopacity, lower-profile delivery systems, better conformability, reduced foreshortening, and enhanced bifurcation management. The competitive landscape is led by established vascular device manufacturers that compete on lesion-specific performance, physician familiarity, procedural simplicity, and their ability to address both routine occlusive disease and more complex aneurysmal anatomy. At the same time, the market continues to face practical constraints such as reimbursement sensitivity in certain healthcare systems, the need for skilled operators, restenosis concerns in difficult lesions, and careful product selection between self-expanding, balloon-expandable, covered, and branch-based solutions. Overall, the market outlook remains favorable, supported by the continued shift toward minimally invasive revascularization and a product pipeline focused on precision, durability, and anatomical versatility.
Key Insights
-
A major historical and continuing influence on the iliac stent market is the transition from open surgical repair to endovascular-first management in aortoiliac disease. This shift has widened the addressable patient pool by making treatment more feasible for elderly, comorbid, and moderate-risk patients, while also increasing demand for devices that support shorter recovery times, efficient procedures, and dependable deployment outcomes in everyday vascular practice.
-
Product segmentation remains one of the most important structural features of the market, with self-expanding, balloon-expandable, and covered stents each serving different lesion and anatomical requirements. Self-expanding systems are favored for flexibility and vessel conformity, balloon-expandable devices for placement precision, and covered stents for complex, calcified, restenotic, or bifurcation lesions where sealing and lesion exclusion can improve clinical confidence and procedural outcomes.
-
A key current technology trend is the increasing importance of branch-preserving iliac devices in aneurysm-related interventions. Iliac branch endoprostheses are expanding the market beyond straightforward occlusive disease by enabling treatment of anatomies where internal iliac artery preservation matters. This has created a more specialized segment in which planning sophistication, physician training, and anatomical suitability play a significant role in product adoption and competitive positioning.
-
The long-term disease burden of peripheral arterial disease remains a major growth driver for the market. Rising prevalence of diabetes, smoking-related vascular damage, hypertension, obesity, and aging-associated arterial disease continues to support the need for iliac interventions. Earlier diagnosis, broader awareness of limb ischemia and mobility impairment, and greater attention to minimally invasive revascularization are strengthening the clinical relevance of iliac stenting in vascular care pathways.
-
Competitive positioning is increasingly defined by lesion-specific engineering rather than overall portfolio size alone. Manufacturers are differentiating through radial strength, radiopacity, deliverability, foreshortening control, conformability, and suitability for bifurcation and complex common iliac artery lesions. This is driving a more anatomy-based purchasing pattern, where physician choice depends heavily on the device’s ability to address routine as well as technically demanding cases with procedural confidence.
-
Hospitals and specialized vascular centers continue to dominate end-use demand, but their purchasing criteria are evolving. Buyers increasingly value products that help standardize minimally invasive workflows, reduce procedural complexity, and improve confidence in lesion coverage and stent deployment. This shift supports platforms that integrate smoothly into catheterization labs and hybrid operating rooms, especially in bilateral, long-lesion, or anatomically difficult interventions where predictability is particularly important.
-
Looking ahead, the market is likely to be shaped by the convergence of precision deployment, complex lesion capability, and broader anatomical customization. Future growth will favor companies that combine strong physician familiarity with platforms designed for calcified disease, bifurcation treatment, restenosis management, and branch-preserving aneurysm repair. In this context, innovation is moving beyond basic patency expectations toward greater procedural versatility and more refined endovascular treatment strategies across diverse iliac anatomies.
Regional Analysis
North America
North America remains one of the most mature markets for iliac stents due to high procedural adoption of endovascular therapy, strong specialist availability, and well-established treatment pathways for aortoiliac disease. The region offers attractive opportunities in premium covered stents, precise balloon-expandable systems, and branch-preserving devices for aneurysm-related anatomies. Current trends favor treatment of more complex lesions, repeat interventions for restenotic disease, and broader use of anatomically tailored devices. The competitive environment is shaped by strong brand loyalty, physician experience, and emphasis on clinical performance, while future demand is expected to remain supported by the ongoing burden of peripheral artery disease and continued preference for minimally invasive revascularization.
Asia Pacific
Asia Pacific is emerging as a high-potential region for the iliac stent market, supported by expanding vascular care infrastructure, growing awareness of peripheral artery disease, and a large patient population affected by diabetes, smoking, and age-related vascular disorders. The region is moving gradually from basic revascularization solutions toward more differentiated device use, including covered stents and products designed for challenging anatomies. Companies have significant room to expand through physician training, access enhancement, and collaboration with high-volume intervention centers. Over the forecast period, the region is expected to gain strategic importance as procedure volumes rise and endovascular therapy becomes more deeply embedded in mainstream vascular treatment.
Europe
Europe represents a technically advanced iliac stent market where clinical practice is strongly influenced by structured vascular care pathways, lesion complexity assessment, and long-standing endovascular expertise. Opportunities are especially strong in covered stents for complex disease, branch-preserving systems for aneurysm management, and premium platforms that offer placement accuracy and durable vessel conformity. Recent market developments reflect a growing focus on complex iliac reconstruction and precise device selection for calcified and bifurcation lesions. The regional outlook remains positive, particularly in specialized centers that prioritize advanced endovascular workflows, while competition continues to reward companies with strong clinical evidence and anatomically specialized solutions.
Middle East & Africa
The Middle East & Africa market is more heterogeneous, with demand concentrated in better-equipped tertiary hospitals, specialty vascular units, and urban referral centers. Gulf countries present stronger opportunities for advanced covered and branch-based devices due to greater investment in minimally invasive cardiovascular care, while other parts of the region remain influenced by limited access, uneven diagnosis, and budget sensitivity. Market development is being supported by the gradual expansion of endovascular capabilities and increasing demand for less invasive treatment in complex vascular patients. Supplier success in the region will depend on clinical training, local distribution strength, and the ability to balance premium innovation with cost-conscious market needs.
South & Central America
South & Central America offers a developing but increasingly meaningful opportunity base for iliac stent suppliers, especially in larger healthcare markets where interventional vascular procedures are becoming more standardized. Demand is linked to the growing burden of cardiometabolic disease and rising interest in endovascular alternatives to open surgery for symptomatic occlusive disease. The market is likely to favor versatile devices that balance performance with affordability, while higher-end product adoption is expected to remain concentrated in referral centers managing complex anatomy. Looking ahead, market expansion will be shaped by physician training, broader procedural access, and stronger commercialization of minimally invasive vascular treatment across the region.
Market Scope
| Parameter | iliac stent market Detail |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Market Size-Units | USD billion |
| Market Splits Covered | By Type, By Artery Lesions, By End-Users |
| Countries Covered | North America (USA, Canada, Mexico) |
| Analysis Covered | Latest Trends, Driving Factors, Challenges, Trade Analysis, Price Analysis, Supply-Chain Analysis, Competitive Landscape, Company Strategies |
| Customization | 10% free customization (up to 10 analyst hours) to modify segments, geographies, and companies analyzed |
| Post-Sale Support | 4 analyst hours, available up to 4 weeks |
| Delivery Format | The Latest Updated PDF and Excel Data file |
Iliac Stent Market Segments Covered In The Report
By Type
- Self-Expandable Stents
- Balloon-Expandable Stents
- Other Types
By Artery Lesions
- Common Iliac Artery Lesions
- Severe Calcified Lesions
- Complete Obstructive Lesions
By End-Users
- Hospitals
- Outpatient Facilities
- Other End-Users
By Geography
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Spain, Italy, Rest of Europe)
- Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Key Market Players
Cardinal Health Inc., Abbott Laboratories, Medtronic Plc, Becton, Dickinson and Company, Boston Scientific Corporation, B. Braun Melsungen AG, Terumo Corporation, W. L. Gore & Associates Inc, C. R. Bard Inc., Getinge AB, Cook Medical LLC, Biotronik SE & Co. KG, MicroPort Scientific Corporation, Cordis Corporation, Endologix Inc., LeMaitre Vascular Inc., Alvimedica, Clearstream Technologies Ltd., Jotec GmbH, Translumina GmbH, Vascular Concepts Limited, Lombard Medical Technologies , Acandis GmbH, Gore Medical, Medizintechnik GmbH
Recent Industry Developments
- July 2025 – Getinge obtained FDA premarket approval for its iCast covered stent system as a bridging stent, allowing doctors to preserve blood flow between a branch vessel and an endovascular graft in aneurysmal disease cases.
- May 2025 – Boston Scientific commenced the ORION clinical trial to evaluate its EPIC Self‑Expanding Nitinol Stent System in treating iliac artery disease, with patient enrollment beginning in the U.S.
- January 2025 – Bentley InnoMed launched its BeFlow iliac covered stent system in Europe at LINC 2025, presenting a cost-efficient covered option for treating occlusive iliac artery diseases.
FAQ's
The Iliac Stent Market is estimated to generate $ 1263 million in revenue in 2025.
The Iliac Stent Market is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.45% during the forecast period from 2025 to 2034.
The Iliac Stent Market is estimated to reach $ 2412 million by 2034.
Didn’t find what you’re looking for? TALK TO OUR ANALYST TEAM
Need something within your budget? NO WORRIES! WE GOT YOU COVERED!
